Tech Company Financing Transactions
Neurexis Therapeutics Funding Round
Neurexis Therapeutics, based in Aurora, secured $3 million in funding from National Institutes of Health.
Transaction Overview
Company Name
Announced On
9/18/2024
Transaction Type
Debt
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This grant will allow Neurexis to further develop tatCN19o, a peptide-based therapeutic that targets the enzyme CaMKII, a crucial player in synaptic plasticity and memory.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
12635 E. Montview Blvd., Bioscience 1 100
Aurora, CO 80045
USA
Aurora, CO 80045
USA
Phone
Website
Email Address
Overview
Neurexis is developing an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Artinger
Chief Operating Officer
Olivia Asfaha
Chief Scientific Officer
Ulli Bayer
VP - R & D
Robyn Goforth
Browse more venture capital transactions:
Prev: 9/18/2024: Edera venture capital transaction
Next: 9/19/2024: Mevo venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs